Comparison Of Monocyte / HDL Ratio In Routine Hemodialysis And Peritoneal Dialysis Patients
Öz
Anahtar Kelimeler
Kaynakça
- 1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Clasification and Stratification. Am J Kidney Dis. 2002; Vol. 39: 1-266
- 2. Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. J Ren Care. 2011; 37: 12–5.
- 3. Tonbul HZ, Demir M, Altintepe L, et al. Malnutrition-Inflammation-Atherosclerosis syndrome componentsin hemodialysis and peritoneal dialysis patients. 2006; 24: 287-94.
- 4. Rao P, Reddy GC, Kanagasabapathy AS. Malnutrition-inflammation-atherosclerosis syndrome in Chronic Kidney disease. Indian J ClinBiochem. 2008; 23: 209–17.
- 5. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transpl. 2002; 17 Suppl 8: 33–8; discussion 40.
- 6. Daugirdas JT, Blake P, Ing TS, et al. Handbook of Dialysis, Fourth Edition. Dial Transplant. 2007; 36: 322.
- 7. Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol. 2006; 80: 1156–64.
- 8. Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979; 32: 213–29.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Alper Sarı
Bu kişi benim
Türkiye
Memnune Sena Ulu
Bu kişi benim
Türkiye
Sinan Kazan
Bu kişi benim
Türkiye
Onur Tunca
Bu kişi benim
Türkiye
Elif Dizen Kazan
Bu kişi benim
Türkiye
Yayımlanma Tarihi
17 Mart 2020
Gönderilme Tarihi
4 Şubat 2020
Kabul Tarihi
5 Mart 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 47 Sayı: 1